Sarepta Therapeutics’ Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-Specified Matched External Control in Part II of Study SRP-9001-102 for the Treatment of Duchenne Muscular Dystrophy

Sarepta Therapeutics, Inc. announced topline results from Part II of Study SRP-9001-102, an ongoing, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety, efficacy and tolerability of a single dose of SRP-9001 in 41 patients with Duchenne muscular dystrophy.